Lyell Immunopharma, Inc.

NASDAQ:LYEL

Biotechnology

Healthcare
$13.89 +1.20%

+$0.15 today

Market cap
$341.49M
Beta
-0.09
P/E (TTM)
-1.1
EPS (TTM)
-$11.26
52W Low $8.46High $45.00

Volume 0.11M

Average 0.09M

LYEL Other Income / Expenses

Net non-operating gains and losses, such as investment results, currency effects, and one-off items.

Lyell Immunopharma, Inc.NASDAQ: LYEL

Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026

Other income / expenses growth accelerates

Q1 FY2026 other income / expenses of $22M rose 325.4% year over year, ahead of the -309.6% change in trailing-twelve-month other income / expenses.

Context

  • Other income / expenses amounted to 196316.7% of revenue in FY2025, up 170479.0 pp from a year earlier.
  • Other income / expenses increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +325.4% holds above the trailing-twelve-month pace of -309.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$22M+127.7% QoQ
Last fiscal yearDec 2025
-$70.67M-548.4% YoY
LTMMar 2026
-$54.54M-309.6% YoY
Other Income / Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+325.4%——
1 year-548.4%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Income / Expenses history

USD · from the income statement

Latest · FY2025
(70.67M) USD
Year-over-year change
-548.4%

Other Income / Expenses vs competitors

How LYEL compares with its peers on the latest reported figures

  • Peers report in different currencies, so other income / expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -309.6% is the lowest of 10, against a peer median of -46.9%.
  • Other income / expenses amounts to 175948.4% of revenue for LYEL, versus a peer median of 39.8%.
LYEL Competitors
Other Income / Expenses for LYEL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$16.46M USD-3.2%——
KYTXKyverna Therapeutics, Inc.LTM Mar 2026$7.39M USD-51.5%+158.9%—
LRMRLarimar Therapeutics, Inc.LTM Mar 2026$6.42M USD-36.5%+80.0%—
EDITEditas Medicine, Inc.LTM Mar 2026$6.16M USD-32.3%—15.9%
CABACabaletta Bio, Inc.LTM Mar 2026$3.97M USD-46.9%+55.6%—
AMRNAmarin Corporation plcLTM Mar 2026$2.64M USD-79.4%—1.2%
GNLXGenelux CorporationLTM Mar 2026$1.99M USD+5.2%—24812.5%
SLNSilence Therapeutics plcLTM Mar 2026$1.43M USD—-50.1%155.2%
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$1.01M USD-70.6%+29.4%—
ACIUAC Immune S.A.LTM Mar 2026-CHF 1.47M CHF-268.3%—39.8%
LYELLyell Immunopharma, Inc.LTM Mar 2026-$54.54M USD-309.6%—175948.4%
Peer median (excluding LYEL) —-46.9%+55.6%39.8%

Competitors are the stored peer set for LYEL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue10.65M84.68M130K61K36K
Cost of Revenue000011.54M
Gross Profit10.65M84.68M130K61K(11.5M)
Gross Margin100.0%100.0%100.0%100.0%-31952.8%
Research & Development138.69M159.19M182.95M171.6M158.68M
Selling, General & Admin89.06M117.31M66.98M52.04M45.14M
Operating Expenses225.43M271.74M247.14M358.82M192.27M
Depreciation & Amortization13.62M18.02M20.25M19.63M11.54M
EBITDA(236.6M)(165.1M)(214.38M)(200.64M)(262.91M)
EBITDA Margin-2221.5%-195.0%-164909.2%-328923.0%-730302.8%
Operating Income(214.78M)(187.06M)(247.01M)(358.76M)(203.77M)
Operating Margin-2016.7%-220.9%-190006.2%-588123.0%-566038.9%
Interest Income1.17M7.05M23.45M24.07M13.08M
Interest Expense00000
Other Income / Expenses(35.44M)3.94M12.38M15.76M(70.67M)
Income Before Tax(250.22M)(183.12M)(234.63M)(342.99M)(274.45M)
Pre-Tax Margin-2349.5%-216.2%-180486.2%-562285.2%-762355.6%
Income Tax Expense00000
Net Income(250.22M)(183.12M)(234.63M)(342.99M)(274.45M)
Net Margin-2349.5%-216.2%-180486.2%-562285.2%-762355.6%
EPS (Basic)(1.03)(0.74)(0.93)(1.31)(16.06)
EPS (Diluted)(1.03)(0.74)(0.93)(1.31)(16.06)
Weighted Avg Shares12.14M12.35M12.55M13.07M17.09M
Weighted Avg Shares (Diluted)12.14M12.35M12.55M13.07M17.09M

Lyell Immunopharma, Inc.

NASDAQ:LYEL

Intrinsic Alpha fair value

Locked

Current Price

$13.89

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.